Loading…
Loading…
Teratogen avoidance, disease flare monitoring, and neonatal lupus risk stratification
Pregnancy in women with rheumatic disease requires meticulous preconception planning, medication reconciliation for teratogen avoidance, disease activity optimisation before conception, and close perinatal monitoring for maternal flare, pre-eclampsia, and fetal complications. At Dr. Shree Narayan's clinic, a multidisciplinary pregnancy planning clinic coordinates rheumatology, obstetric, and neonatal care. Disease activity in the 6 months before conception is the strongest predictor of flare during pregnancy and adverse outcomes. Key teratogens requiring discontinuation include methotrexate, leflunomide, mycophenolate mofetil, and JAK inhibitors, all of which must be discontinued at least 3 to 6 months before attempted conception.
Kathmandu Neurology Clinic & Cognitive Center
Authored and reviewed by Dr. Shree Narayan Yadav (MBBS (KU), MD-Internal Medicine (NAMS), MSc Clinical Rheumatology (USW, UK), NMC 14227). Evidence-based, no fabricated outcomes.
Pregnancy in women with rheumatic disease requires meticulous preconception planning, medication reconciliation for teratogen avoidance, disease activity optimisation before conception, and close perinatal monitoring for maternal flare, pre-eclampsia, and fetal complications. At Dr. Shree Narayan's clinic, a multidisciplinary pregnancy planning clinic coordinates rheumatology, obstetric, and neonatal care. Disease activity in the 6 months before conception is the strongest predictor of flare during pregnancy and adverse outcomes. Key teratogens requiring discontinuation include methotrexate, leflunomide, mycophenolate mofetil, and JAK inhibitors, all of which must be discontinued at least 3 to 6 months before attempted conception.
Reviewed by Dr. Shree Narayan Yadav, MBBS, MD, MSc — Consultant Physician & Joint and Autoimmune Disease Specialist (NMC 14227), Kathmandu Neurology Clinic. For evaluation, book an appointment.
A structured medication review at least 6 months before planned conception is essential. Methotrexate (folate antagonist, teratogenic) must be discontinued at least 3 months before conception, with folic acid supplementation initiated immediately. Leflunomide requires active elimination with cholestyramine (washout protocol) and a minimum 3-month washout period. Mycophenolate mofetil is absolutely contraindicated in pregnancy due to increased risk of miscarriage, cleft palate, and ear abnormalities. JAK inhibitors have limited human data and should be discontinued. Conversely, hydroxychloroquine, sulfasalazine, azathioprine, tacrolimus, and low-dose prednisolone are considered safe and should be continued throughout pregnancy.
SLE pregnancies carry increased risk of flares (approximately 50-60%), pre-eclampsia (20-30%), preterm delivery, and fetal growth restriction. Active nephritis at conception significantly increases pre-eclampsia and preterm birth risk. Anti-Ro/SSA and anti-La/SSB antibodies cross the placenta and cause neonatal lupus (congenital heart block, rash, cytopenias) in 1-2% of exposed pregnancies; cardiac manifestations are permanent and may require lifelong pacing. Antiphospholipid syndrome (APS) in pregnancy requires low-dose aspirin plus prophylactic or therapeutic LMWH depending on antibody profile and prior obstetric history.
The postpartum period is a high-risk time for disease flare, particularly in SLE, where flare rates increase to 50-70% in the first 6 months after delivery. Medications that were discontinued during pregnancy for teratogenic reasons can be restarted promptly after delivery. Breastfeeding is encouraged and compatible with most DMARDs including hydroxychloroquine, azathioprine, sulfasalazine, tacrolimus, and low-dose prednisolone (less than 20 mg/day). Methotrexate and leflunomide are contraindicated during breastfeeding. Anti-TNF agents (certolizumab, adalimumab) are detectable in breast milk in very low concentrations and are considered compatible with breastfeeding per current evidence.
Flint J et al. BSR guidelines for the management of rheumatic diseases in pregnancy. RheumatologySammaritano LR et al. 2020 ACR guideline for the management of reproductive health in RA and SLE. Arthritis RheumatolBrucato A et al. Prevention of congenital heart block in anti-Ro/SSA-positive pregnancies. CirculationContent on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.